An Experience on Pomalidomide in Patients within Relapsed/Refractory Multiple Myeloma - A Multicenter Study in Turkey
Mehmet Ali Erkurt, Fehmi Hindilerden, Omer Ekinci, Jale Yildiz, Mehmet Sinan Dal, Metin Bagci, Tuba Hacibekiroglu, Mehmet Hilmi Dogu, Sinem Namdaroglu, Abdulkadir Basturk, Emine Gulturk, Mustafa Merter, Bugra Saglam, Sinan Demircioglu, Duzgun Ozatli, Ahmet Sarici, Turgay Ulas, Serdal Korkmaz, Bulent Eser & Fevzi Altuntas · Journal of Pharmaceutical Research International · 2021
Objective: Pomalidomide is a new generation thalidomide analogue. Effectiveness as a single agent or combination with low dose dexamethasone has been in the treatment of relapse/refractory Multiple Myeloma (MM). The aim of the present study was to share the experience of differen...